ProteoNic Launches 2G UNic Transposon Platform for Enhanced Biologics Production
核心洞察
ProteoNic (搜索) announced the commercial launch of its novel 2G UNic (搜索) transposon platform (搜索), combining proven vector technology with proprietary transposon systems for superior cell line productivity.
The platform demonstrates more than two-fold increases in titers, supporting production levels up to 10 g/L for complex biologics and difficult-to-express proteins.
The technology expands compatibility across mammalian and yeast cell platforms while reducing development timelines and manufacturing costs.
ProteoNic (搜索), a leader in premium vector technology for biologics and cell and gene therapy, announced on September 15, 2025, the commercial launch of its novel 2G UNic (搜索) transposon platform (搜索). The platform combines the company's proven 2G UNic vector technology with a proprietary transposon system to deliver cell lines with superior productivity, stability, and shorter development timelines.
Platform Performance and Applications
The new 2G UNic (搜索) transposon platform (搜索) has demonstrated more than a two-fold increase in titers, supporting production levels of up to 10 g/L. This technology is applicable across mammalian and yeast cell platforms and product classes, creating new opportunities for customers advancing complex biologics and difficult-to-express proteins.
"We are proud to announce the development and launch of our novel 2G UNic (搜索) transposon platform (搜索) that takes productivity, flexibility, and ease of use in cell line generation to the next level," said Frank Pieper, CEO of ProteoNic (搜索). "By also expanding our premium 2G UNic vector technology to support other transposon systems, we can now offer customers maximum flexibility."
Expanded Technology Offering
ProteoNic (搜索) is simultaneously expanding its 2G UNic (搜索) vector technology offering to include application to existing third-party transposon systems. This expansion allows customers to improve established workflows with a premium vector backbone that boosts performance for cell line generation, regardless of the underlying platform.
At the core of ProteoNic (搜索)'s approach is its 2G UNic (搜索) vector technology, proven to deliver significant productivity gains by increasing titers of complex biologics and reducing manufacturing costs. Now modified and optimized for compatibility with all transposon platforms, 2G UNic enables customers to maximize performance regardless of the underlying system, cell type, or product class.
Therapeutic Applications
In addition to applications in therapeutic antibody and protein production, ProteoNic (搜索)'s transposon platform (搜索) holds promise for stable producer cell line generation in cell and gene therapy, opening new opportunities for partners across the biopharmaceutical landscape.
Commercial Availability
The launch follows a series of successful evaluations with industry partners and marks the full commercial availability of both the 2G UNic (搜索) transposon platform (搜索) and expanded 2G UNic vector technology capabilities for licensing. The new platform was presented publicly at BioProcess International (BPI), part of Biotech Week Boston, highlighting the platform's ability to deliver meaningful improvements in productivity and development speed for complex biologics.